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Abstract
Background: Patients with contact to healthcare-system in high-prevalence countries (HPC) and refugee patients in
hospital settings (REF) have previously been identified to be at risk of carrying multidrug-resistant organisms
(MDRO). Comparative studies addressing the epidemiology of MDRO in patients transferred from hospitals abroad
(ABROAD) and REF are lacking but are necessary to introduce refined infection control measures.
Methods: From December 2015 to June 2016, 117 REF, 84 ABROAD and 495 patients admitted to intensive care unit,
with no refugee history or pre-treatment abroad (ICU), at University Hospital Frankfurt, Germany (UHF) were screened
for MDRO on day of admittance. Data within these groups were compared and set in an epidemiological context.
Results: 52.1% (95% confidence interval = 42.7-61.5) of REF and 41.6% (31.0-52.9) of ABROAD, were positive for at least
one MDRGN, respectively. In contrast, 7.9% (5.6-10.6) of ICU were positive for MDRGN. Thereof, 0.9% (0.0-4.7) of REF, 15.
5% (8.5-25.0) of ABROAD and 0% (0.0-0.7) of ICU were positive for at least one MDRGN with carbapenem resistance
(CR). In total, 19 MDRGN with CR were detected in ABROAD, with the most frequent species with CR being A.
baumannii with 42.1% (20.3-66.5). Regarding MRSA, 10.3% (5.4-17.2) of REF, 5.9% (1.9-13.3) of ABROAD and a
significantly lower proportion 1.4% (0.6-2.9) of ICU, respectively, were tested positive.
Conclusions: Both REF and ABROAD pose a relevant hospital hygiene risk. High prevalence of MDRGN with CR in
ABROAD was observed. Concise screening and infection control guidelines are needed in patient cohorts with
increased risk for MDRO carriage.
Keywords: Multidrug-resistant organisms, Refugees, Medical tourists, Infection control, Hospital hygiene
Background
Traveling to high-prevalence countries (HPC) for
multidrug-resistant organisms (MDRO), such as multidrug-
resistant Enterobacteriaceae and Acinetobacter baumannii
(MDRGN) and methicillin-resistant Staphylococcus aureus
(MRSA), as well as contact with the local healthcare-system
in HPC have previously been identified as risk factors to for
acquiring MDRO [1–9]. UHF is located in the direct vicin-
ity of the Frankfurt international airport which processes al-
most 60 million passengers per year [10]. German residents
returning after pre-treatment in healthcare-system in HPC,
medical travelers seeking healthcare in Germany as well as
travelers who experience medical problems during transit
represent a relevant number of patients admitted to UHF.
Refugee patients’ countries of origin (COO) have previ-
ously been described as HPCs [11–13]. Since 2015, refugee
influx to Germany has been high [12]. Concise hygiene
management strategies therefore are required not only for
refugees (REF) [11], but also for patients admitted from
health-care systems abroad (ABROAD). Since the first
study addressing the prevalence of multidrug-resistant or-
ganisms (MDRO) in refugee patients in hospital settings
has been published in January 2016 [11], wide-ranging
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experiences in management of REF in European hospitals
have been achieved. However, apart from a recent Dutch
investigation [13], further data on MDRO in REF are avail-
able only to limited degree. This study therefore addresses
the epidemiology of MDRO in refugee patients compared
to patients after pre-treatment in hospitals abroad admitted
to UHF between December 2015 and June 2016. Further-
more, these data were compared to the epidemiology of
MDRO of residents, without any history of fleeing or pre-
treatment abroad, within the same period. These data are
needed to highlight challenges in terms of hospital hygiene




We retrospectively evaluated data of 117 patients admit-
ted from refugee accommodations (REF) to UHF between
December 2015 and June 2016. All REF were systematic-
ally screened via rectal and nasal swabs for MDRO, i.e.
MRSA and MDRGN. MDRGN are defined as Enterobac-
teriaceae with extended spectrum beta-lactamase (ESBL)–
phenotype as well as Enterobacteriaceae, Pseudomonas
aeruginosa, and Acinetobacter baumannii resistant against
Piperacillin, any 3rd/4th generation cephalosporin, and
fluoroquinolones. MDRGN with additional resistance to
carbapenems (CR) are assigned to “MDRGN with CR”.
This approach is according to the hygiene plan of the Uni-
versity Hospital Frankfurt (UHF) and has previously been
described [11]. In addition, 84 patients admitted from
abroad (ABROAD), e.g. foreigners admitted to UHF for
reasons of medical tourism or resident patients admitted
to UHF for further treatment after initial treatment in for-
eign hospitals were screened for MDRO during the obser-
vational period. However, due to language difficulties in
patient anamnesis, data concerning details (length of stay
in hospitals abroad etc.) could not systematically be ex-
plored. We furthermore evaluated the MDRO prevalence
among 495 German resident patients without refugee his-
tory or documented pre-treatment abroad, admitted to a
intensive care unit (ICU) at UHF. Patients admitted for
follow-up treatment from abroad or with refugee history
were excluded from this ICU cohort.
We furthermore assume that vascular and thoracic sur-
gery patients are more likely patients with long-term hos-
pital history compared to traumatology patients (injured
by e.g. road accidents). We therefore additionally investi-
gated the MDRGN prevalence in surgical subgroup.
Group ascertainment for REF and ABROAD
Subjects were fully assessed and assigned to groups ac-
cording to several aspects. Distinguishability was covered
by several aspects: first, we examined the patient data files
for records of hospital stays abroad, residential status in a
refugee accommodation, or records indicating a history of
refugee status. We then investigated differences in funding
of healthcare services also helped to distinguish patients
into ABROAD and REF groups; German patients admit-
ted from abroad are more likely to have health insurance
whereas non-German patients from abroad (without refu-
gee status) more commonly pay directly for services.
Infection control measurements
According to German infection protection law (“Infek-
tionsschutzgesetz”) it is mandatory for hospitals to execute a
documented infection control strategy intended to prevent
the transmission of infective agents and their potential
harmful consequences on patients’ health. At UHF, all pa-
tients admitted from hospitals in HPC or arriving from
refugee accommodations are pre-emptively isolated and
screened for MDRO on day of admission. Screening pro-
cedure also applies to patients without history of pre-
treatment abroad or refugee status admitted to an intensive
care unit (ICU). Immediately after negative results for
MDRGN and MRSA are available, patients are released
from isolation. In case of a positive MDRGN and/or MRSA
result, patients will remain in isolation during their entire
stay at UHF to prevent MDRO transmission, as previously
described [11].
Detection of MDRGN and molecular resistance analysis
All laboratory testing was performed under strict quality-
controlled criteria (laboratory accreditation according to
ISO 15189:2007 standards; certificate number D–ML–
13102–01–00, valid through January 25th, 2021). Rectal
swabs were collected using culture swabs with Amies col-
lection and transport medium (Hain Lifescience, Nehren,
Germany) and streaked onto selective CHROMagarTM
ESBL plates (Mast Diagnostica, Paris, France). Identification
of presumed MDRGN species was done by matrix-assisted-
laser desorption ionization-time of flight analysis (MALDI–
TOF) and VITEK2 (bioMérieux, Nürtingen, Germany).
Antibiotic susceptibility testing was performed according to
Clinical and Laboratory Standards Institute (CLSI) guide-
lines using VITEK 2 and antibiotic gradient tests (bioMér-
ieux). Carbapenemase encoding genes were detected via
PCR analysis and subsequent sequencing from
carbapenem-resistant Enterobacteriaceae including the bla
genes for carbapenemases NDM, VIM, IMP, OXA–48,
OXA–48 like and KPC as well as OXA–23, OXA–24,
OXA–51, and OXA– 58 for A. baumannii [14–16].
Detection of MRSA and determination of spa type
For the detection of MRSA, nasal swabs were inoculated
on Brilliance MRSA Agar (Oxoid, Wesel, Germany).
Identification of MRSA was done by MALDI–TOF and
antibiotic susceptibility testing according to CLSI guide-
lines using VITEK 2. Clonal identity of MRSA isolates
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Table 1 Patient characteristics in REF, ABROAD and ICU
REF ABROAD ICU
number of patients 117 84 495
mean age; standard deviation (years) 19; 14.7 54; 24.0 66; 14.4
male (n; %; 95%CI) 85; 72.7; 63.6-80.5 59; 70.2; 59.3-79.7 341; 68.9; 64.6-72.9
COO a / admitted from (n; %)
Afghanistan 30; 25.6 1; 1.2 residents without
refugee history or
pre-treatment abroadSyria 29; 24.8 -
Somalia 8; 6.8 3; 3.6
Algeria 7; 5.9 1; 1.2
Iraq 5; 4.3 1; 1.2
Pakistan 5; 4.3 -
Eritrea 5; 4.3 2; 2.4
Ethiopia 3; 2.6 3; 3.6
Turkey - 11; 13.1
Greek - 4; 4.8
Italy - 4; 4.8
Morocco - 4; 4.8
Nigeria - 4; 4.8
India - 3; 3.6
Iran - 3; 3.6
Kuwait - 3; 3.6
Croatia - 2; 2.4
Ghana - 2; 2.4
Hungary - 2; 2.4
Saudi-Arabia - 2; 2.4
Spain - 2; 2.4
Sri Lanka - 2; 2.4
Thailand - 2; 2.4
Egypt 2; 1.7 4; 4.8
Other 8; 6.8 b 19; 22.6 c
Unknown 15; 12.8 -
department patients admitted
to (n; %; 95%CI)
intensive care unit - - 495; 100
Surgery 13; 11.1; 0.6-18.3 12; 14.3; 7.6-23.6 495; 100; 99.3-100
general / vascular 6; 5.1 1.9-10.8 4; 4.7; 1.3-11.7 153; 30.9; 26.8-35.2
thoracic - 2; 2.3; 0.2-8.3 273; 55.2; 50.7-59.6
traumatology 7; 5.9; 2.4-11.9 6; 7.1; 2.7-14.9 69; 13.9; 11.0-17.3
Internal medicine 20; 17.1; 10.8-25.2 39; 46.4; 35.5-57.6
Infectious diseases 10; 8.5; 4.1-15.2 9; 10.7; 5.0-19.4 -
Gastroenterology 3; 2.6; 0.5-7.3 9; 10.7; 5.0-19.4
Pneumology 2; 1.7; 0.2-6.0 5; 5.9; 1.9-13.3
Hematology / Oncology - 9; 10.7; 5.0-19.4
Cardiology 3; 2.6; 0.5-7.3 7; 8.3; 3.4-16.4
Angiology 1; 0.9; 0.0-4.7 -
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was analyzed by staphylococcal protein A (spa) typing
using the Ridom StaphType software (Ridom GmbH,
Würzburg, Germany) [17].
Statistical analysis
Chi squared test was performed for statistical analysis.
95% confidence intervals (95% CI) for frequencies were
calculated based on binomial distribution and used to
confirm statistical significance. P-value calculations were
not used to evaluate statistical significance as it has been
criticized for low reliability [18].
Results
Between December 2015 and June 2016, 117 REF and 84
ABROAD and 495 ICU were screened for MDRGN and
MRSA by rectal and nasal swabs, respectively. The me-
dian age of REF, ABROAD and ICU was 19, 54 and
66 years, respectively. In the REF, the most frequently
reported country of origin was Afghanistan (25.6%). The
most frequently reported country ABROAD were admit-
ted from was Turkey (13.1%). REF and ABROAD were
most frequently admitted to the department of pediatrics
(37.6%) and neurology (15.5%), respectively, as given in
Table 1.
The prevalence of at least one MDRGN in REF,
ABROAD and ICU amounted to 52.1% (95% CI =42.7-
61.5), 41.6% (31.0-52.9) and at a significantly lower
prevalence 7.9% (5.6-10.6), respectively. Thereof, 0.9%
(0.0-4.7) of REF, 15.5% (8.5-25.0) of ABROAD and 0%
(0.0-0.7) of ICU, were positive for at least one MDRGN
with additional carbapenem resistance (CR).
Six ABROAD were found positive for more than one
MDRGN species with CR, resulting in a total number of
19 MDRGN with CR in ABROAD. Thereof, the most
frequently detected MDRGN with CR in ABROAD was
A. baumannii with 42.1% (20.3-66.5).
Interestingly, no significant difference was found in
the overall prevalence of MDRGN between REF and
ABROAD, however, the prevalence of MDRGN with CR
in ABROAD (15.5%; 8.5-25.0) significantly exceeded the
prevalence of MDRGN with CR in REF (0.9%; 0.0-4.7)
by 17-fold (Table 2). The prevalence of at least one
MDRGN with CR in both REF and ABROAD signifi-
cantly exceeded the prevalence of MDRGN with CR in
ICU (0%; 0.0-0.7). All carbapenemases detected are given
in Table 2. Of the 117 REF tested, 61 were tested posi-
tive for at least one MDRGN, three individuals were
found positive for two different MDRGN each and one
individual was found positive for three different
MDRGN, resulting in a total number of 66 MDRGN in
REF. Of the 84 ABROAD thested, 35 patients were
tested positive for at least one MDRGN, three individ-
uals were positive for two different MDRGN each, two
individuals were positive for three MDRGN each, and
two individuals were positive for four different MDRGN
each, resulting in a total number of 48 MDRGN in
ABROAD. Of note, two individuals were tested positive
for three different MDRGN with CR each: n = 1 with A.
baumannii, K. pneumoniae and E. coli, and n = 1 with A.
baumannii, K. pneumoniae and Proteus mirabilis. In
contrast, all of 495 ICU were tested single-positive for
MDRGN, resulting in 39 MDRGN in this group.
The most common MDRGN in REF, ABROAD and
ICU was E. coli expressing resistance due to ESBL and
additional resistance to fluoroquinolones (Table 2), with
34/117 (29.1%; 21.0-38.2) in REF, 17/84 (20.2%; 12.3-
30.4) in ABROAD, and, significantly lower, 19/495 (3.8%;
2.3-5.9) in ICU (Table 2). Furthermore, 10.3% of samples
(5.4-17.2) in REF and 4.8% of samples (1.3-11.7) in
ABROAD, respectively, were positive for MRSA. The
prevalence of MRSA in ICU (1.4%; 0.6-2.9) was signifi-
cantly lower compared to REF. Spa types detected in
REF, ABROAD and ICU are given in Table 2.
Furthermore, we found a low prevalence of MDRGN
in the REF, ABROAD and ICU surgical group (Table 2).
In particular, in the traumatology ICU group, the preva-
lence of MDRGN was lowest with 4.3% (0.9-12.2).
Discussion
The rapid global spread of MDRO is a serious global
health risk and must direct attention to the development
of effective strategies to prevent the spread of antibiotic
Table 1 Patient characteristics in REF, ABROAD and ICU (Continued)
Rheumatology 1; 0.9; 0.0-4.7 -
Gynecology / Obstetrics 10; 8.5; 4.1-15.2 3; 3.6; 0.7-10.1 -
Urology 6; 5.1; 1.9-10.8 1; 1.2; 0.0-6.5
Pediatrics 44; 37.6; 28.8-47.0 8; 9.5; 4.2-17.9
Neurology 4; 3.4; 0.9-8.5 13; 15.5; 8.5-25.0
Psychiatrics 7; 5.9; 2.4-11.9 1; 1.2; 0.0-6.5
otherd 12; 10.3; 5.4-17.2 7; 8.3; 3.4-16.4
(a) COO = country of origin; (b) = Albania, Iran, Jordan, Kosovo, Libya, Sudan, Tunisia, and Uganda with n = 1 each; (c) = Azerbaijan, Bangladesh, Bosnia, Bulgaria,
Canada, China, Cuba, Cameroon, Denmark, Dominican Republic, Kazakhstan, Mozambique, Poland, Sudan, Taiwan, Togo, UK, USA, and Uzbekistan with n = 1 each;
(d) = Ear-Nose-Throat (ENT), ophthalmology, orthopedics, and dermatology
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Table 2 Microbiological findings in REF, ABROAD and ICU
REF ABROAD ICU
number of patients 117 84 495
patients positive for at
least one MDRGN (n;%; 95% CI)
61; 52.1; 42.7-61.5 35; 41.6; 31.0-52.9 39; 7.9; 5.6-10.6
subgroup surgery
general / vascular 4; 66.7; 22.2-96.6 1; 25; 0.6-80.6 22; 14.4; 9.2-20.9
thoracic - 1; 50; 12.6-98.7 14; 5.1; 2.8-8.5
traumatology 3; 42.9; 9.9-81.6 2; 33.3; 4.3-77.7 3; 4.3; 0.9-12.2
patients positive for at least
one MDRGN with CR (n;%; 95%CI)
1; 0.9; 0.0-4.7 13; 15.5; 8.5-25.0 0; 0; 0.0-0.7
total number of MDRGN 66 48 40
total number of MDRGN with CR 1 19 -
Escherichia coli
ESBL (n;%; 95CI) 24; 20.5; 13.6-28.9 5; 5.9; 1.9-13.3 14; 2.8; 1.5-4.7
ESBL/FQ (n;%;95CI) 34; 29.1; 21.0-38.2 17; 20.2; 12.3-30.4 19; 3.8; 2.3-5.9
ESBL/FQ + CR (n;%;95CI) 1; 0.9; 0.0-4.7 2; 2.4; 0.3-8.3 -




ESBL (n;%;95CI) 3; 2.6; 0.5-7.3 - 1; 0.2; 0.0-1.1
ESBL/FQ (n;%;95CI) 4; 3.4; 0.9-8.5 5; 5.9; 1.9-13.3 2; 0.4; 0.0-1.5
ESBL/FQ + CR (n;%;95CI) - 7; 8.3; 3.4-16.4 -








Ceph/FQ (n;%;95CI) - 2 a; 2.4; 0.3-8.3 4 b; 0.8; 0.2-2.1
Ceph/FQ + CR (n;%;95CI) - 1 c; 1.2; 0.0-6.5 -
carbapenemase (n) - none detected (1) -
Acinetobacter baumannii
Ceph/FQ (n;%;95CI)
Ceph/FQ + CR (n;%;95CI)
- - -
- 8; 9.5; 4.2-17.9 -
carbapenemase (n) d - OXA-23 (4)
OXA-24 (1)
OXA-58 (1)
NDM-1 + OXA-23 (1)
OXA-23 + OXA-24 (1)
-
Pseudomonas aeruginosa
Pip/Ceph/FQ + CR (n;%;95CI) - 1; 1.2; 0.0-6.5 -
carbapenemase (n) - none detected (1) -
patients positive for MRSA
(n;%; 95% CI)
12; 10.3; 5.4-17.2 4; 4.8; 1.3-11.7 7; 1.4; 0.6-2.9
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resistances and life-threatening infections caused by
MDRO. Diligent prevention strategies of MDRO trans-
mission in hospital settings should therefore be the focus
of preventive efforts. Traveling to HPC, medical tourism,
contact to local health care systems as well as history of
refugee status have previously been identified as risk fac-
tors for carrying MDRO [1–11, 19, 20].
The objective of our study was to give a firm insight
into the epidemiology of MDRO in refugee patients
(REF), patients admitted from abroad (ABROAD) and
German resident patients admitted to a intensive care
unit at UHF (ICU). The major strength of our investiga-
tion is the direct comparison of these three groups as
this issue for our knowledge has not been addressed in
scientific literature so far.
No significant difference in the overall prevalence of
MDRGN between REF and ABROAD was found, the
prevalence of MDRGN with CR in ABROAD (15.5%),
however, significantly exceeded the prevalence in REF
(0.9%) by 17-fold (Table 2). This phenomenon might re-
flect an inherent risk to acquire highly resistant MDRGN
in hospitals in HPC, from which the majority of ABROAD
are admitted from to UHF, such as e.g. Turkey, Egypt,
Ethiopia or Somalia (Table 1). For repatriates, this aspect
has previously also been mentioned by Josseaume et al.
[8]. Considering that conditions under which refugees
make their way to Germany might have been poor, we
hypothesize that refugees in good health condition are
more likely to make the journey than refugees suffering
from severe disease or disability and with a strong history
of hospital treatment in their country of origin. We how-
ever cannot quantify the level of contact REF have had
with their local health care system, which therefore might
be a source of bias in our setting. In a future setting, it
therefore might be interesting to evaluate the MDRO
prevalence in refugees without any contact to their local
health care system compared to refugees without.
Our data thus indicate, that ABROAD are more likely
to represent the prevalence of highly resistant bacteria in
hospitals abroad, whereas REF are more likely to portray
the general prevalence of highly resistant bacteria in
their COO. Furthermore, this finding is additionally
underlined by previous findings showing a high
prevalence of A. baumannii with CR in hospitals in Syria
and Iran [21–24].
However, due to language barriers, data regarding e.g.
exact previous medical treatment or length of stay in the
hospitals abroad was available only in a minority of REF
patients as well as a low number of ABROAD patients.
This aspect could be interesting to evaluate the time-
frame that MDRO might be acquired within in hospitals
abroad. Moreover, exact phylogeny analysis of isolated
resistant strains (e.g., via NGS techniques) was not per-
formed which might have demonstrated a potential
clonal spread of resistant pathogens in some particular
countries of patients from ABROAD.
In the traumatology ICU group we found a MDRGN
prevalence of 4.3% (0.9-12.2), which is in the range of
general German population’s MDRGN prevalence [25].
Concerning prevalence of MRSA, no significant differ-
ence between REF (10.3%; 5.4-17.2) and ABROAD
(4.8%; 1.3-11.7) was observed, even though MRSA
prevalence in ICU (1.4%; 0.6-2.9) was significantly lower
than in REF (Table 2). This finding might reflect the lim-
ited space conditions in refugee accommodations: in
parallel with e.g. an outbreak of measles in a refugee
settlement in Calais, France, [26], or clustering of shigel-
losis in refugees in Austria [27]. The conditions refugees
live in might also be conducive to the spread of MRSA
within the community. Investigating the spa types in the
three cohorts, we found ICU patients harbouring spa
types known to be common in Germany, e.g. t003, t020,
or t223 [28, 29]. In contrast, many of the spa types de-
tected in REF (t131, t304, t325, t790, t4892; Table 2)
have frequently been recorded from e.g. Iran, Jordan,
United Arab Emirates or Lebanon [28]. However, the
number of MRSA detected in REF in this study (n = 12)
seems to be too low to assess any epidemiological
trends.
These mentioned countries are in immediate neigh-
bourhood to the most frequently recorded COO of REF
in this study (e.g. Afghanistan and Syria, Table 1), which
might indicate that REF bring new spa types to Germany
and Europe. For future settings, we suggest to perform
genotyping on the core chromosomes, e.g. via multilocus
sequence typing (MLST), whole genome sequencing or
Table 2 Microbiological findings in REF, ABROAD and ICU (Continued)
t325 (1)
t386 (1)






Abbreviations: CR carbapenem resistance, ESBL extended spectrum beta-lactamase, ESBL/FQ ESBL and additional resistance to fluoroquinolones, Ceph/FQ resistance
to cephalosporins and additionally to fluoroquinolones, Pip/Ceph/FQ + CR resistance to Piperacillin and additionally Ceph/FQ + CR, MRSA methicillin-resistant
Staphylococcus aureus
(a) =Morganella morganii, Proteus mirabilis (n = 1 each); (b) = Enterobacter cloacae, Serratia marcescens, Proteus mirabilis, and Morganella morganii (n = 1 each); (c) =
Proteus mirabilis; (d) = other than species-specific OXA-51
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SCCmec typing for MRSA, and plasmid typing for more
exact phylogenetic and epidemiological investigations.
Conclusions
In summary, our findings demonstrate a significant and
inherent risk for REF and ABROAD to carry MDRGN
and MRSA. While it is hardly possible to predict
whether these MDRGN and MRSA strains will have evo-
lutionary advantage in German population or in German
hospitals, this investigation revealed the indispensability
of screening programs and appropriate hygiene measure-
ments in refugee patients as well as in patients pre-
treated in hospitals abroad. In particular, the overwhelm-
ing high proportion of MDRGN with CR in patients
after pre-treatment in hospitals abroad should be con-
sidered by domestic healthcare systems. Therefore, this
risk must be covered by adequate hospital infection con-
trol measurements. Based on our findings, we feel a
strong need to implement a concise screening procedure
for patients arriving from abroad as well as refugee pa-
tients. This should also include German residents after
pre-treatment in hospitals abroad. We therefore suggest
screening for MDRO on day of admittance as well as
pre-emptive isolation for both groups.
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